Latest Health News

Anagenics Limited has revealed a significant 52.6% decline in revenue alongside an 83.5% increase in net loss for the financial year ended June 2025, marking a challenging period for the biotech company.

Farm Pride Foods Ltd has reported a remarkable 384% increase in net profit for the financial year ending June 2025, despite revenues remaining virtually unchanged. The company’s financial health shows signs of strengthening, though no dividends were declared.

Vitasora Health reported a sharp rise in losses and operating cash outflows for FY2025, despite achieving significant cost savings from its Orb Health acquisition. The company faces a material uncertainty over its ability to continue as a going concern.

Clinuvel Pharmaceuticals has reported a robust financial year ending June 2025, marked by solid revenue growth and sustained profitability, while advancing its clinical pipeline and maintaining a strong balance sheet.

EMVision Medical Devices reported a sharp increase in FY25 losses alongside a 51% revenue drop, yet marked significant progress in clinical trials for its innovative brain scanners and secured $8 million in government grants to fuel commercialisation.

De.mem Limited reported a 19.7% increase in revenue to $13.96 million for the half-year ended June 2025, alongside a 42% reduction in net loss and its first positive adjusted EBITDA in years. Strategic acquisitions and expansion into Asian domestic markets underpin the company’s improving financial health.

Comms Group delivered FY25 results at the upper end of guidance, boosted by record new sales and the acquisition of TasmaNet. The company sets sights on accelerated growth and integration benefits in FY26.

Rhythm Biosciences has formalised a strategic co-marketing partnership with the Know Your Lemons Foundation to promote its geneType Breast Cancer Risk Assessment Test, expanding access to early detection tools for women in the US and Australia.

Starpharma has received a $3.7 million R&D Tax Incentive refund for the 2025 financial year, reinforcing its commitment to advancing dendrimer technology and biotechnology innovation in Australia.

PointsBet Holdings Limited has issued a supplementary statement urging shareholders to reject betr Entertainment’s increased scrip offer, reaffirming support for MIXI Australia’s competing cash bid. The board highlights risks tied to betr’s offer and underscores the superior value of the MIXI proposal.

RAS Technology Holdings Limited reported a robust 31% revenue increase to $21.3 million in FY25, achieving its first after-tax profit following a strategic acquisition in Hong Kong that expanded its Asian footprint and recurring revenue.

dorsaVi appoints Mathew Regan as Group CEO to spearhead commercialisation of next-gen RRAM-enabled AI and robotics technologies, aiming for global expansion.